Johnson & Johnson Venture Fund Participates in $100 Million Financing Round for Delix Therapeutics
Johnson & Johnson's venture capital arm, JJDC, has joined a $100 million financing round for Delix Therapeutics, a private biotechnology company. The funding is specifically earmarked to advance the development of psychedelic-based treatments aimed at addressing various neurological disorders. This investment signals growing institutional interest in the psychedelic medicine sector as a legitimate frontier for pharmaceutical innovation. By backing Delix, Johnson & Johnson is positioning itself within the emerging landscape of neuro-psychiatric drug development through its venture capital division.
Tickers: $JNJ
Topics: biotechnology financing round neurological disorders venture capital